8-K: Matinas BioPharma Announces Complete Clinical Response in Three Patients with Invasive Fusarium Infection Using Oral MAT2203

Matinas BioPharma reports successful clinical outcomes in three patients with serious invasive fusarium infections treated with their oral antifungal drug candidate, MAT2203.

Summary

• Matinas BioPharma announced that three patients with serious invasive fusarium infections achieved complete clinical response after being treated with MAT2203, an oral formulation of amphotericin B.
• These patients were part of the company's Compassionate/Expanded Use Access Program.
• The patients had infections resistant to other antifungals, including azoles and intravenous amphotericin B, which caused nephrotoxicity in one patient.
• One patient, a 40-year-old female with extensive burns, had a soft tissue fusarium infection that resolved after two weeks of oral MAT2203 treatment.
• Another patient, a 48-year-old female renal transplant recipient, had chronic leg wounds due to a fusarium infection that healed completely after six months of MAT2203 treatment.
• The third patient, a 69-year-old male with lung cancer, showed improvement in his lung infection after six months of outpatient treatment with oral MAT2203.
• These results add to the 19 patients previously discussed in the MAT2203 Compassionate/Expanded Use Access Program update, with two of these three patients not having achieved complete resolution at the time of the previous report.

Sentiment

Score: 8

Explanation: The document presents very positive clinical results for a difficult-to-treat infection, which is a significant positive for the company. However, the risks associated with clinical trials and the need for additional capital temper the overall sentiment.

Positives

• MAT2203 demonstrated the ability to resolve deadly fungal infections in patients with limited treatment options.
• The oral formulation of MAT2203 offers a potential alternative to intravenous amphotericin B, which is associated with significant safety issues.
• The successful outcomes in these patients increase confidence for the upcoming ORALTO Phase 3 trial in patients with invasive aspergillosis.
• MAT2203 has the potential to become a new treatment paradigm for invasive fungal infections if approved.

Negatives

• The patients treated had serious underlying conditions and complex medical challenges in addition to their fungal infections.
• MAT2203 is still in development and is not yet licensed or approved anywhere globally.

Risks

• The company's ability to obtain additional capital to meet its liquidity needs is a risk.
• There are uncertainties inherent in clinical testing and obtaining regulatory approvals.
• The company faces competition and changes in the regulatory landscape.
• The company's product candidates are all in a development stage and are not available for sale or use.

Future Outlook

Matinas BioPharma plans to further evaluate MAT2203 in a Phase 3 registration trial (ORALTO) as an oral step-down monotherapy for invasive aspergillosis.

Management Comments

• Theresa Matkovits, PhD, Chief Development Officer of Matinas, stated that the complete clinical response is gratifying given the difficulty in treating fusarium infections.
• Jerome D. Jabbour, Chief Executive Officer of Matinas, said that MAT2203 has demonstrated the ability to resolve deadly infections, allowing physicians to focus on other underlying conditions.

Industry Context

The announcement highlights the potential of oral antifungal treatments to address the limitations of current intravenous options, particularly in cases of drug-resistant infections. This is relevant given the increasing prevalence of antifungal resistance and the need for new treatment paradigms.

Comparison to Industry Standards

• The successful treatment of fusarium infections with MAT2203 is notable, as these infections are often resistant to commonly used antifungals like azoles and echinocandins.
• Current standard treatment for severe fungal infections often involves intravenous amphotericin B, which is associated with significant side effects like nephrotoxicity, which MAT2203 aims to avoid with its oral delivery.
• The development of oral alternatives to intravenous antifungals is a key area of focus in the industry, with companies like Gilead Sciences and Pfizer also working on new antifungal therapies.
• The results from Matinas BioPharma are promising when compared to the limited treatment options currently available for patients with invasive fusarium infections.

Stakeholder Impact

• Shareholders may view the positive clinical results as a positive development.
• Patients with invasive fungal infections may benefit from the development of MAT2203.
• The company's employees may be motivated by the positive clinical outcomes.

Next Steps

• Matinas BioPharma will further evaluate MAT2203 in the ORALTO Phase 3 trial for invasive aspergillosis.
• The company will continue to pursue development and partnership opportunities for its products and platform technology.

Key Dates

Keywords

MAT2203, Matinas BioPharma, Fusarium Infection, Amphotericin B, Antifungal, Invasive Fungal Infections, Oral Treatment, Clinical Response, LNC Platform, Compassionate Use